Anebulo Pharmaceuticals and FDA Collaborate on Selonabant Development
Anebulo Pharmaceuticals (ANEB) has recently announced a pivotal regulatory update regarding the development of intravenous selonabant, aimed at addressing acute cannabis-induced toxicity in children. This announcement follows the completion of a Phase 2 proof-of-concept study, which demonstrated selonabant's efficacy in blocking or reversing key CNS effects of THC in 134 adult subjects.
Clinical Progress and FDA Engagement
The company has engaged in discussions with the FDA to outline the initial plan for clinical testing of intravenous selonabant. The FDA has recognized the critical unmet need for a treatment targeting children exposed to cannabis toxicity and has proposed a close, ongoing collaboration to expedite the development of selonabant for this pediatric indication. Anebulo Pharmaceuticals plans to commence its Phase I Single Ascending Dose (SAD) study of IV selonabant in healthy adults in the first half of 2025.
Financial Developments
In support of its research and development efforts, Anebulo Pharmaceuticals has successfully closed a capital raise, securing $15 million through a private placement. This funding was achieved via the issuance and sale of 15.2 million shares of common stock, priced at-the-market under Nasdaq rules. The capital raise involved 22NW, a company controlled by one of Anebulo's directors, Nantahala Capital, and an additional existing investor. As part of this financial arrangement, Anebulo intends to modify its existing loan and security agreement with 22NW and JFL Capital Management, reducing the maximum loan size to approximately $3 million and eliminating any securitization.
This strategic financial and regulatory advancement underscores Anebulo Pharmaceuticals' commitment to addressing a significant public health challenge and marks a critical step forward in the development of a much-needed therapeutic option for acute cannabis-induced toxicity in children.
